2 terminated, 1 completed, 1 withdrawn. 4 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Terminated 2, Completed 1, Withdrawn 1 |
| Phase 3 | 1 | Withdrawn 1 |
Follow Rottapharm: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Randomized Study for the Assessment of Silibinin (Legalon® SIL) in the Treatment of naïve Genotype 4 Patients With Chronic Hepatitis C Legalon® SIL (Silibinin), Pegylated interferon alfa2b, Ribavirin - Hepatitis C, Chronic | Phase 2 / Phase 3 | Withdrawn | Rottapharm | 2013-08-01 | 2015-03-05 | |
| Silymarin for the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) Sillymarin, Placebo - Non-alcoholic Fatty Liver Disease | Phase 2 | Completed | University of Malaya | 99 | 2012-06-01 | 2016-01-08 |
| Effect of LEGALON SIL on Hepatitis C Virus Recurrence in Stable Liver Transplanted Patients Silibinin (Legalon-SIL), Saline - Hepatitis C Virus Recurrence | Phase 2 | Terminated | Rottapharm | 20 | 2011-08-01 | 2015-03-05 |
| Legalon SIL for the Treatment of HCV Recurrence in Liver Transplanted Patients Silibinin, Placebo - HCV Recurrence After Liver Transplantation | Phase 2 | Terminated | Rottapharm | 14 | 2010-09-01 | 2012-02-17 |
Hepatitis C (1) · Hepatitis C, Chronic (1) · Non-alcoholic Fatty Liver Disease (1)
Silybin (3) · Ribavirin (1) · Silymarin (1) · Sodium Chloride (1) · peginterferon alfa-2b (1)
Egypt (1) · Italy (1) · Malaysia (1)
Alfredo Di Leo, MD (1) · Gamal Esmat, MD (1) · Samer El-Kamary, MD (1) · Sanjiv Mahadeva, MD, MRCP (1) · Xavier Forns, Dr (1)